EVALUATION OF THE EFFICACY OF BIORESONANCE (MORA) THERAPY IN PATIENTS WITH TREATMENT-RESISTANT CHRONIC MIGRAINE

DR ÖMER SOYAK, NEUROLOGY SPECIALIST/SAMSUN

INTRODUCTION
Migraine is a heterogeneous disease that causes significant loss of function at work and in life outside work. It is a neurovascular disease that affects approximately 12% of the general population. It is characterized by attacks of nausea, vomiting, phonophobia, photophobia and severe throbbing headache. Many cellular and molecular mechanisms, including normal neuronal excitability and vascular events, play a role in the pathogenesis of migraine. Antidepressants, calcium channel blockers, antiepileptic drugs and angiotensin converting enzyme inhibitors are used for migraine prophylaxis (1-2). These drugs regulate different ion channels and neurotransmitter systems, reducing neuronal excitability, and central or peripheral pain sensitization.
In a headache epidemiology study conducted in our country, the prevalence of migraine in the 15-55 age group was found to be 16.4%, and this rate was determined as 21.8% for women and 10.9% for men (3). The severity of pain and associated sysytems may vary between individuals (4). Having moderate or severe pain that affects daily activity is one of the diagnostic criteria for migraine and is observed in approximately 70% of patients (5). When a headache occurs, some patients report having to leave work and go home, while others say they cannot leave their jobs but experience reduced productivity. The World Health Organization (WHO) defines this condition, which completely prevents or restricts people's normal activities, as a disability (6). Although there are many tools developed to measure the disability, one of the most widely used scales is the Migraine Disability Assessment Scale (MIDAS) (7).

PATIENTS AND METHOD
The study included five patients (4 women [80%] and 1 man [20%]) who were diagnosed with episodic migraine according to the International Headache Classification II, resistant to treatment, and frequently experiencing attacks. (8). All patients had migraine without aura. Those with diseases other than episodic migraine were not included in the study. Neurological examinations and routine laboratory tests of the patients were normal. MIDAS tests were administered to the patients, determining the MIDAS score, total number of days with headaches, and attack frequency for each patient. All prophylactic migraine medications were discontinued, and patients underwent bioresonance (MORA Therapy). MORA Therapy sessions were applied in two cycles: attack and non-attack. During attacks, only color therapy and analgesics were placed in the MTI cup, while Biorhythm, 14th or 15th program, color and bach flowers were used in the non-attack period. The patients were not given any medical treatment during the treatment period. However, after the treatment was completed, simple analgesics were recommended for use in attacks. The MIDAS scores of the patients were between 4 and 10. It is generally accepted that disability begins when pain intensity reaches the level of "5" on a 0-10 scale (9).

RESULTS
While the average MIDAS score of the patients was 8 for the 3 months before the start of treatment, the average MIDAS score was determined as 2 during a 3-month treatment period. The attacks, which did not respond to any medical treatment before and caused social and workforce loss, decreased by 80% and even responded to simple analgesics.

DISCUSSION
The importance of migraine in terms of public health may be overlooked due to its episodic course and the fact that it does not cause mortality. However, migraine often interferes with social activity and work life and leads to significant drug consumption (10). In a Turkish study, it was found that the loss of labor due to migraine was 5.4 days per year (3).
Many factors are implicated for the pathogenesis of migraine. There are many studies showing vitamin B12 and folic acid deficiencies, iron accumulation, and deficiencies or accumulations in some biochemical parameters in patients with migraine (11, 12). But even discussing whether these are a result or a cause is a waste of time.
Many cellular and molecular mechanisms, including abnormal neuronal excitability and neurovascular events, play a major role in the pathogenesis of migraine. The fact that MORA Therapy is so effective in terms of treatment may be due to its regulatory effect on neuronal excitability and the neurovascular system.
In conclusion, MORA Therapy should be considered as the first choice rather than an alternative in migraine treatment. Bioresonance Therapy should now take its place in scientific and academic circles, and its mechanism of action should be investigated. Perhaps a complete unraveling of its mechanism of action could fully explain the pathogenesis of migraine and cause it to be classified as a completely treatable disease.
Isn't it time for this change?

REFERENCES

1. Galletti F, Cupini LM, Corbelli I, Calabresi P, Sarchielli P. Pathophysiological
basis of migraine prophylaxis. Prog Neurobiol
2009;89:176-92.
2. Schiapparelli P, Allais G, Castagnoli Gabellari I, Rolando S, Terzi
MG, Benedetto C. Non-pharmacological approach to migraine
prophylaxis: part II. Neurol Sci 2010;31(Suppl 1):S137-9.
3. Hayran O, Zarifo¤lu M, Siva A. Bafla¤r›s› Epidemiyolojisi. Erdine S
(Ed). A¤r›. 2000;181-183.
4. Bigal ME, Lipton RB. Migraine at all ages. Curr Pain Headache Rep
2006;10:207-217.
5. D’Amico D, Usai S, Grazzi L. and et al. Disability and migraine:
M‹DAS. J Headache Pain 2001;2:25-27.
6. Bussone G, Grazzi L, Usai S. and et al. Disability in Migraine patients
Italian experience. J Headache Pain 2001;2:29-31.
7. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman
JN, Sawyer J. An international study to assess reliability of the
Migraine Disability Assesment (MIDAS) score. Neurology
1999;53:988-994.
8. Headache Classification Committee of the International Headache
Society. The international classification of headache disorders.
2nd ed. Cephalalgia 2004;24(Suppl 1):S32-3.
9. Borkum J. Predicting Disability from Headache; Handbook of
Complex Occupational Disability Claims. Ed: Izabela Z Schultz and
Robert J Gatchel. USA Springerlink; 2005: s:255-272.
10. Téllez-Zenteno JF, García-RamosG, Zermeño-Pöhls, Velazquez A.
Demographic, clinical and comorbidity data in a large sample of
1147 patients with migraine in Mexico City. J Headache Pain.
2005;6:128-134.
11. Abdullah A, Osman E, Ertuğrul U. Migren hastalarında Serum
Vitamin B12 ,Folik Asit ve Ferritin Düzeyleri. Turk Norol Derg 2011;17:90-95
12. Kruit MC, Launer LJ, Overbosch J, van Buchem MA, Ferrari MD.
Iron accumulation in deep brain nuclei in migraine: a populationbased magnetic resonance imaging study. Cephalalgia
2009;29:351-9.